The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations

Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, et al. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Curr Oncl 2023 Sep 27;30(10):8805-8814. doi:10.3390/curroncol30100635

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

Falk M, Schatz S, Reich FPM, Schmidt S, Galster M, Tiemann M, et al. Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Curr. Oncol. 2023 Sep 28;30(10):8865-8871. doi:10.3390/curroncol30100640

A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay

Menon R, et al. A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. J Thorac Oncol 2016 Sep;11(9):e105-7. doi:10.1016/j.jtho.2016.04.005

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens

Müller J, et al. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. J Thorac Oncol 2017 Oct;12(10):1503-1511. doi:10.1016/j.jtho.2017.07.014

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Plenker D, et al. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clin Canc Res 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001